These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27761161)

  • 1. Molecular pathogenesis of long QT syndrome type 2.
    Smith JL; Anderson CL; Burgess DE; Elayi CS; January CT; Delisle BP
    J Arrhythm; 2016 Oct; 32(5):373-380. PubMed ID: 27761161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long QT Syndrome Type 2: Emerging Strategies for Correcting Class 2
    Ono M; Burgess DE; Schroder EA; Elayi CS; Anderson CL; January CT; Sun B; Immadisetty K; Kekenes-Huskey PM; Delisle BP
    Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32759882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visualizing Mutation-Specific Differences in the Trafficking-Deficient Phenotype of Kv11.1 Proteins Linked to Long QT Syndrome Type 2.
    Hall AR; Anderson CL; Smith JL; Mirshahi T; Elayi CS; January CT; Delisle BP
    Front Physiol; 2018; 9():584. PubMed ID: 29875689
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum.
    Smith JL; Reloj AR; Nataraj PS; Bartos DC; Schroder EA; Moss AJ; Ohno S; Horie M; Anderson CL; January CT; Delisle BP
    Am J Physiol Cell Physiol; 2013 Nov; 305(9):C919-30. PubMed ID: 23864605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism.
    Anderson CL; Delisle BP; Anson BD; Kilby JA; Will ML; Tester DJ; Gong Q; Zhou Z; Ackerman MJ; January CT
    Circulation; 2006 Jan; 113(3):365-73. PubMed ID: 16432067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promise and Potential Peril With Lumacaftor for the Trafficking Defective Type 2 Long-QT Syndrome-Causative Variants, p.G604S, p.N633S, and p.R685P, Using Patient-Specific Re-Engineered Cardiomyocytes.
    O'Hare BJ; John Kim CS; Hamrick SK; Ye D; Tester DJ; Ackerman MJ
    Circ Genom Precis Med; 2020 Oct; 13(5):466-475. PubMed ID: 32940533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic basis for type 2 long QT syndrome caused by KCNH2 mutations that disrupt conserved arginine residues in the voltage sensor.
    McBride CM; Smith AM; Smith JL; Reloj AR; Velasco EJ; Powell J; Elayi CS; Bartos DC; Burgess DE; Delisle BP
    J Membr Biol; 2013 May; 246(5):355-64. PubMed ID: 23546015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intragenic suppression of trafficking-defective KCNH2 channels associated with long QT syndrome.
    Delisle BP; Slind JK; Kilby JA; Anderson CL; Anson BD; Balijepalli RC; Tester DJ; Ackerman MJ; Kamp TJ; January CT
    Mol Pharmacol; 2005 Jul; 68(1):233-40. PubMed ID: 15851652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel intracellular transport-refractory mutations in KCNH2 identified in patients with symptomatic long QT syndrome.
    Fukumoto D; Ding WG; Wada Y; Fujii Y; Ichikawa M; Takayama K; Fukuyama M; Kato K; Itoh H; Makiyama T; Omatsu-Kanbe M; Matsuura H; Horie M; Ohno S
    J Cardiol; 2018 Apr; 71(4):401-408. PubMed ID: 29146210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of Kv11.1 potassium channel PAS-domain variants trafficking via machine learning.
    Immadisetty K; Fang X; Ramon GS; Hartle CM; McCoy TP; Center RG; Mirshahi T; Delisle BP; Kekenes-Huskey PM
    J Mol Cell Cardiol; 2023 Jul; 180():69-83. PubMed ID: 37187232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The KCNH2-IVS9-28A/G mutation causes aberrant isoform expression and hERG trafficking defect in cardiomyocytes derived from patients affected by Long QT Syndrome type 2.
    Mura M; Mehta A; Ramachandra CJ; Zappatore R; Pisano F; Ciuffreda MC; Barbaccia V; Crotti L; Schwartz PJ; Shim W; Gnecchi M
    Int J Cardiol; 2017 Aug; 240():367-371. PubMed ID: 28433559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. hERG quality control and the long QT syndrome.
    Foo B; Williamson B; Young JC; Lukacs G; Shrier A
    J Physiol; 2016 May; 594(9):2469-81. PubMed ID: 26718903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational insights into the mechanisms underlying structural destabilization and recovery in trafficking-deficient hERG mutants.
    AlRawashdeh S; Mosa FES; Barakat KH
    Front Mol Biosci; 2024; 11():1341727. PubMed ID: 39193219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The proteostasis interactomes of trafficking-deficient variants of the voltage-gated potassium channel K
    Egly CL; Barny LA; Do T; McDonald EF; Knollmann BC; Plate L
    J Biol Chem; 2024 Jul; 300(7):107465. PubMed ID: 38876300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A High-Throughput Screening Assay to Identify Drugs that Can Treat Long QT Syndrome Caused by Trafficking-Deficient K
    Egly CL; Blackwell DJ; Schmeckpeper J; Delisle BP; Weaver CD; Knollmann BC
    Mol Pharmacol; 2022 Apr; 101(4):236-245. PubMed ID: 35125346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model.
    Mehta A; Ramachandra CJA; Singh P; Chitre A; Lua CH; Mura M; Crotti L; Wong P; Schwartz PJ; Gnecchi M; Shim W
    Eur Heart J; 2018 Apr; 39(16):1446-1455. PubMed ID: 29020304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients With Long-QT Syndrome Caused by Impaired
    Hyltén-Cavallius L; Iepsen EW; Wewer Albrechtsen NJ; Svendstrup M; Lubberding AF; Hartmann B; Jespersen T; Linneberg A; Christiansen M; Vestergaard H; Pedersen O; Holst JJ; Kanters JK; Hansen T; Torekov SS
    Circulation; 2017 May; 135(18):1705-1719. PubMed ID: 28235848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of three heterozygous KCNH2 mutation-carrying human induced pluripotent stem cell lines for modeling LQT2 syndrome.
    Mondéjar-Parreño G; Jahng JWS; Belbachir N; Wu BC; Zhang X; Perez MV; Badhwar N; Wu JC
    Stem Cell Res; 2021 Jul; 54():102402. PubMed ID: 34051449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput discovery of trafficking-deficient variants in the cardiac potassium channel K
    Kozek KA; Glazer AM; Ng CA; Blackwell D; Egly CL; Vanags LR; Blair M; Mitchell D; Matreyek KA; Fowler DM; Knollmann BC; Vandenberg JI; Roden DM; Kroncke BM
    Heart Rhythm; 2020 Dec; 17(12):2180-2189. PubMed ID: 32522694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of CAV3 in long-QT syndrome: clinical and functional assessment of a caveolin-3/Kv11.1 double heterozygote versus caveolin-3 single heterozygote.
    Hedley PL; Kanters JK; Dembic M; Jespersen T; Skibsbye L; Aidt FH; Eschen O; Graff C; Behr ER; Schlamowitz S; Corfield V; McKenna WJ; Christiansen M
    Circ Cardiovasc Genet; 2013 Oct; 6(5):452-61. PubMed ID: 24021552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.